Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer

Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer

Immune checkpoint blockade represents a major breakthrough in advanced non-small cell lung cancer (NSCLC) therapy. However, success is limited to a subset of patients and there is a critical need to identify robust biomarkers associated with clinical response. In this study, we assessed whether pre-...

Full description

Bibliographic Details
Main Authors: Selene Ottonello, Carlo Genova, Irene Cossu, Vincenzo Fontana, Erika Rijavec, Giovanni Rossi, Federica Biello, Maria Giovanna Dal Bello, Marco Tagliamento, Angela Alama, Simona Coco, Simona Boccardo, Irene Vanni, Guido Ferlazzo, Lorenzo Moretta, Francesco Grossi, Maria Cristina Mingari, Paolo Carrega, Gabriella Pietra
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Immunology
Subjects:
nivolumab
PD-1
biomarkers
non-small-cell lung cancer
peripheral blood
immune checkpoint
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.00125/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.00125/full

Similar Items